‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio<scp>CAPTURE</scp>network

Reek, J.M.P.A. van den; Zweegers, Jeffrey; Kievit, Wietske; Otero, M.E.; Lümig, P.P.M. van; Driessen, R.J.B.; Ossenkoppele, P.M.; Njoo, M. D.; Mommers, J.M.; Koetsier, M.I.A.; Arnold, W.P.; Sybrandy-Fleuren, B.A.M.; Kuijpers, A.L.A.; Andriessen, M.P.M.; Kerkhof, P.C.M. van de; Seyger, M.M.B.; Jong, E.M.G.J. de

doi:10.1111/bjd.13087

Cited by 92 publications

(92 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 3 summarizes all the studies published so far, where data were collected from large patient population of two or more centers, the follow-up period was at least one year, and the authors compared at least three or more biological therapies. The list includes five prospective registry-based studies and three retrospective studies (5,11,(16)(17)(18)(19)(20). Table 3 shows that those studies which included ustekinumab have found drug survival of ustekinumab superior to the drug survival of TNF-alpha inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

Pogácsás

Borsi

Takács

et al. 2017

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Persistence is an important component of therapeutic success, which depends on a variety of factors. Persistence measured under optimal conditions during clinical trials does not necessarily coincide with persistence observed in the real-world settings. The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a retrospective analysis. Drug survival rate has been calculated according to Kaplan-Meier analysis and Cox regression was used to study the predictors. The overall persistence rate for the four biologicals exceeded 60% after 3 years. The persistence rate of ustekinumab at 3 years was 67.83%, which was superior compared to that of the TNF-alpha inhibitors, where the mean persistence rate was shown to be 50.76% (p < .05). Male patients showed significantly higher persistence than females (HR ¼ .76, p < .05 CI: 0.63, 0.92). Age, therapy-naïve status and use of concomitant MTX did not have significant effect on drug survival. Persistence rate of ustekinumab was significantly higher than that of TNF-alpha inhibitors, and among predictors, only male gender influenced persistence significantly. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

Pogácsás

Borsi

Takács

et al. 2017

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…A new concept of “happy drug survival” was introduced by combining quality of life measures with drug survival [73]. In a recent study based on BioCAPTURE registry data, the percentage of treatment episodes with “happy on-drug patients” increased from 27% at baseline to 79% after 1 year.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival

Costanzo¹,

Malara²,

Pelucchi³

et al. 2018

Dermatology

View full text Add to dashboard Cite

Psoriasis is a complex and chronic disease, and, in most cases, therapies are required during all patients’ lifetime. The efficacy and safety profiles of biological therapies are well established, but their effectiveness is still open to discussion. We performed a systematic review to summarize how the effectiveness of biological therapies for psoriasis is measured in real-world studies and to understand whether drug survival, a recent alternative outcome to clinical ones, is a recurrent and valid outcome of effectiveness. In March 2017, we searched for quantitative epidemiological data of psoriasis treatments using PubMed/Medline and EMBASE, and we included 65 publications. The retrospective study design (37%) was most frequent, followed by prospective registries (29%), prospective studies (19%), and retrospective administrative databases/claims. Drug survival was reported in over 60% of prospective registries and retrospective studies, and less frequently in prospective studies. A general consensus emerged in the definition of drug survival as the time patients remain under treatment with a specific therapy, and in its interpretation as an overall marker of treatment success and treatment adherence, as it represents simultaneously information on drug efficacy, drug safety, and patient satisfaction. In conclusion, notwithstanding some limitations, drug survival is a useful measurement of biological therapy effectiveness for psoriasis in daily practice. Its major advantage is that it can be computed also in already collected databases without any specific clinical information on psoriasis. This outcome, combined with evidence on clinical markers of effectiveness, can contribute to better understanding the performance of this expensive class of drugs.

show abstract

“…Bezüglich der Therapiepersistenz ("Drug survival") von Biologika bei Psoriasis ist die Datenlage teilweise uneinheitlich, und Langzeitdaten sind relativ rar [34][35][36][37] . Van den Reek et al fanden 1-Jahres-Persistenzraten von 85 % für Ustekinumab, 74 % für Adalimumab und 68 % für Etanercept [ 38 ] , Ergebnisse, die weitgehend mit Daten von Clemmensen et al übereinstimmen [ 39 ] . Eine andere Arbeitsgruppe do-Tabelle 3 Multivariate Regressionsmodelle zur Erfassung des Einflusses von soziodemografischen Charakteristika, Schwere und Dauer der Erkrankung, der Anzahl der systemischen Psoriasis-Therapien und der Therapiezufriedenheit auf die RIS von Prozesseigenschaften.…”

Section: Patienten Mit Einer Langen Krankheitsdauer Ein Besonderesunclassified

“…Levine und Kollegen identifi zierten Infl iximab als das Biologikum mit der größten Nachhaltigkeit und Ustekinumab als das Biologikum mit der geringsten Abbruchrate [ 41 ] . Erstens waren einige Studien monozentrisch [ 40,41 ] , während andere "Drug-survival"-Raten in großen landesweiten Kohorten untersuchten [34][35][36][37][38] . Die Unterschiede in den "Drug survival"-Raten können teilweise durch die Heterogenität der verschiedenen Studien erklärt werden.…”

Section: Patienten Mit Einer Langen Krankheitsdauer Ein Besonderesunclassified

Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability

Kromer

Peitsch

Herr

et al. 2017

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTUREnetwork

Cited by 92 publications

References 36 publications

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival

Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability

Contact Info

Product

Resources

About